Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure.
Por:
de la Espriella R, Bayés-Genís A, Llàcer P, Palau P, Miñana G, Santas E, Pellicer M, González M, Górriz JL, Bodi V, Sanchis J and Núñez J
Publicada:
1 ene 2022
Ahead of Print:
8 sep 2021
Resumen:
BACKGROUND: This study aimed to evaluate whether glomerular filtration rate (eGFR) during admission modifies the predictive value of plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) in patients hospitalized for acute heart failure (AHF). METHODS: We retrospectively evaluated 4595 patients consecutively discharged after admission for AHF at three tertiary-care hospitals from January 2008 through October 2019. To investigate the effect of kidney function on the association of NT-proBNP and CA125 with 1-year mortality (all-cause and cardiovascular mortality), we stratified patients according to four eGFR categories: <30 mL•min(-1)•1.73 m(-2), 30-44 mL•min(-1)•1.73 m(-2), 44-59 mL•min(-1)•1.73 m(-2), and =60 mL•min(-1)•1.73 m(-2). Biomarkers were assessed within the first 24 hours following admission. RESULTS: At 1-year follow-up, 748 of 4595 (16.3%) patients died after discharge (of all deaths, 575 [12.5%] were cardiovascular). After multivariate adjustment, both NT-proBNP and CA125 remained independently associated with a higher risk of death when modeled as main effects (P<0.001). However, we found a differential prognostic effect of NT-proBNP across eGFR categories for both endpoints (all-cause mortality, P-value for interaction=0.002; CV mortality, P-value for interaction=0.001). Whereas NT-proBNP was positively and linearly associated with mortality in the subset of patients with normal or mildly reduced eGFR, its predictive ability progressively decreased at the lower extreme of eGFR (<45 mL•min(-1)•1.73 m(-2)). In contrast, the association between CA125 and survival remained consistent across all eGFR categories (all-cause mortality, P-value for interaction=0.559; CV mortality, P-value for interaction=0.855). CONCLUSIONS: In patients with AHF and severely reduced eGFR, CA125 outperforms NT-proBNP in predicting 1-year mortality.
Filiaciones:
de la Espriella R:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
:
CIBER Cardiovascular, Madrid, Spain
Cardiology Department and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona. Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain
Llàcer P:
Internal Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
Palau P:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
Miñana G:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
Santas E:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
Pellicer M:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
González M:
Nephrology Department. Hospital Clínico Universitario de Valencia, Universitat de València. Valencia, INCLIVA, Valencia, Spain
Górriz JL:
Nephrology Department. Hospital Clínico Universitario de Valencia, Universitat de València. Valencia, INCLIVA, Valencia, Spain
Bodi V:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
CIBER Cardiovascular, Madrid, Spain
Sanchis J:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
CIBER Cardiovascular, Madrid, Spain
Núñez J:
Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain
CIBER Cardiovascular, Madrid, Spain
Bronze
|